IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease

Summary

Double-masked, dose-response, trial of IVW-1001 in subjects with dry eye disease.

Timeline

Start

2024-06-25

Primary completion

2024-10-15

Completion

2024-10-15

Outcome

Met primary endpoint

release “IVW-1001, a first-in-class TRPM8 agonist delivered via a proprietary eyelid wipe, achieved statistically significant improvements in both signs and symptoms” iviewtherapeutics.com ↗

release “statistical significance on both key sign and key symptom endpoints” iviewtherapeutics.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IVW-1001	Unknown	0.1 %	Other
Subject	IVW-1001	Unknown	0.2 %	Other

Indications